Tyrosine Kinase Inhibitors (TKIs), like nilotinib and dasatinib, are effective treatments available for Chronic Myeloid Leukaemia (CML) and found to interact with ABCB1 and ABCG2. The gene discussed is ABCB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.